Thomas D. Nolin

Dr. Thomas Nolin is a tenured Associate Professor in the Department of Pharmacy & Therapeutics, and in the Department of Medicine Renal-Electrolyte Division at the University of Pittsburgh. Dr. Nolin’s primary research focuses on developing an understanding of the impact of kidney disease and renal replacement therapy (RRT) on nonrenal metabolism and transport pathways and corresponding effects on drug exposure and response. Dr. Nolin has a strong record of interdisciplinary and interinstitutional collaborations with regulatory, pharmaceutical industry, and academic scientists in the conduct of a broad range of clinical-translational and population health studies in patients with kidney disease. He has served as chair of the Kidney Health Initiative workgroup (a joint effort between the U.S. FDA and the American Society of Nephrology) to assess pharmacokinetics during RRT, as co-chair of the Extracorporeal Treatments in Poisoning (EXTRIP) Workgroup, and as an invited panelist on FDA advisory committees addressing nephropharmacology-related topics. Dr. Nolin has published over 150 manuscripts and book chapters and has presented more than 175 scientific abstracts and invited talks. He serves on the editorial board of the Clinical Journal of the American Society of Nephrology, and as an Editor of the textbook Pharmacotherapy: A Pathophysiological Approach. He is a Fellow of the American College of Clinical Pharmacy, the American College of Clinical Pharmacology, and of the American Society of Nephrology.